Pathological classification of brain tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 2, 2012, Pages 103-111

  Pollo, B ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Biological markers; Brain neoplasms; Glioma; Pathology

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ASTROCYTOMA; BRAIN TUMOR; CANCER GENOME ATLAS PROJECT; CANCER GRADING; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE SIGNATURE; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN GENOME PROJECT; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; NEUROPATHOLOGY; ONCOGENE; ONCOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; GENETIC MARKERS; GLIOMA; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84864393644     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Louis DN, Ohgaki H, Wiestier OD, Cavenee WK, editors. WHO Classification of tumors of the central nervous system. Lyon: IARC; 2007.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
3. Weiler M. Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly 2011;141:w13210.
4. Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol 2011;70:101-9.
5. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010;9:717-26.
6. Riemenschneider MJ, Jeuken JWM, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010;120:567-84.
7. van den Bent MJ, Kros JM. Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol 2007;66:1074-81. (Pubitemid 350294657)
8. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
9. Sulman EP, Aldape K. The use of global profiling in biomarker development for gliomas. Brain Pathology 2011;21:88-95.
10. Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W et al. Molecular diagnostics of gliomas: the clinical perspective Acta Neuropathol 2010;120:585-92.
11. Nagarajan RP, Costello JF. Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 2009;6:436-46.
12. Polio B. Neuropathological diagnosis of brain tumors. Neurol Sci 2011;32(Suppl 2):209-11.
13. Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. British Journal of Cancer 2011;104:545-53.
14. Colman H, Aldape K. Molecular predictors in glioblastoma. Toward personalized therapy. Arch Neurol 2008;65:877-83. (Pubitemid 352008470)
15. Gravendeel LAM, Kouwenhoven MCM, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009;69:9065-72.
16. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
17. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep 2011;11:291-7.
18. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73. (Pubitemid 43357943)
19. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D et al. Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545-51. (Pubitemid 46869696)
20. Grier JT, Batchelor T Low-grade gliomas in adults. Oncologist 2006;11:681-93. (Pubitemid 43967623)
21. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 2011;17:4588-99.
22. Schiff D, Brown P, Giannini C. Outcome in adult low-grade glioma. The impact of prognostic factors and treatment. Neurology 2007;69:1366-73. (Pubitemid 47482451)
23. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45. (Pubitemid 30078545)
24. Eoli M, Bissola L, Bruzzone MG, Polio B, Maccagnano C, De Simone T et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119:84-90.
25. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. O MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
26. Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L, Polio B et al. Methylation of 06-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clinical Cancer Res 2007;13:2606-13. (Pubitemid 46788026)
27. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 2008;67:1-15.
28. von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathology 2011;21:74-87.
29. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 2011;28:177-83.
30. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177:2708-14.
31. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4.
32. Labussiere M, Sanson M, Idbaih A, Delattre JY. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 2010;15:196-9.
33. Labussière M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010;74:1886-90.
34. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560-6.
35. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJB, Wesseling P et al. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16:1597-604.
36. Capper D, Weißen S, Balss J, Habell A, Meyer J, JägerD et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathology 2010;20:245-54.
37. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-Oncology 2010;12:621-30.
38. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641-9.
39. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405.
40. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6. (Pubitemid 40315227)
41. Sjöström S, Andersson U, Liu Y, Brännström T, Broholm H, Johansen C et al. Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro-Oncology 2010;12:815-21.
42. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. N Engl J Med 2005;353:2012-24. (Pubitemid 41609094)
43. Pelloski CE, Ballman KV, Furth AF, Zhang L, E. Lin, Sulman EP et al. Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma. J Clin Oncol 2007;25:2288-94. (Pubitemid 46954657)
44. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathology 2009;19:713-23.
45. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther 2008;7:1321-5.
46. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 2009;14:621-36.
47. Rivera CG, Mellberg S, Claesson-Welsh L, Bader JS, Popel AS. Analysis of VEGF-a regulated gene expression in endothelial cells to identify genes linked to angiogenesis. PLoS One 2011;6:e24887.
48. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep 2009;9:254-62.
49. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 2010;24:2205-18.